Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 7/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.53 |
| ▸ | MAPT | P10636 | 6/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | NR1I2 | O75469 | 4/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.53 |
| ▸ | TSHR | P16473 | 3/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.53 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.53 |
| ▸ | PGR | P06401 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
| ▸ | AR | P10275 | 2/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.53 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5425553 | 1.00 | LMNA (0.64) | LMNACYP3A4MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL571724 | 0.99 | LMNA (0.62) | LMNACYP3A4MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL5331 | 0.99 | LMNA (0.62) | LMNACYP3A4MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL8015127 | 0.97 | LMNA (0.60) | LMNACYP3A4MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL2561836 | 0.93 | CYP3A4 (0.56) | LMNACYP3A4MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL28255051 | 0.92 | CYP3A4 (0.59) | LMNACYP3A4MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL976275 | 0.90 | CYP3A4 (0.56) | LMNACYP3A4MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL11023737 | 0.89 | CYP3A4 (0.60) | LMNACYP3A4MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL15861556 | 0.88 | CYP3A4 (0.55) | LMNACYP3A4MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL2042111 | 0.88 | CYP3A4 (0.58) | LMNACYP3A4MAPTSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160008376-A1 | Compositions, Methods and Uses for Treating Gender-Biased Immune Disorders | BIOCOPEA LIMITED (GB) | 2016-01-14 | — | — | US | claimed |
| WO-2016005599-A1 | COMPOSITIONS, METHODS AND USES FOR TREATING GENDER-BIASED IMMUNE DISORDERS | BIOCOPEA LIMITED (GB) | 2016-01-14 | — | — | WO | claimed |
| EP-2286818-B1 | Fulvestrant formulation | ASTRAZENECA AB (SE) | 2020-03-18 | — | — | EP | disclosed |
| US-20190298646-A1 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY CONDITIONS | INITIUM INNOVATIONS, INC. | 2019-10-03 | — | — | US | disclosed |
| US-20160008376-A1 | Compositions, Methods and Uses for Treating Gender-Biased Immune Disorders | BIOCOPEA LIMITED (GB) | 2016-01-14 | — | — | US | disclosed |
| WO-2016005599-A1 | COMPOSITIONS, METHODS AND USES FOR TREATING GENDER-BIASED IMMUNE DISORDERS | BIOCOPEA LIMITED (GB) | 2016-01-14 | — | — | WO | disclosed |
| EP-1250138-B2 | FULVESTRANT FORMULATION | ASTRAZENECA AB (SE) | 2015-07-08 | — | — | EP | disclosed |
| EP-2266573-B1 | Fulvestrant formulation | ASTRAZENECA AB (SE) | 2015-06-17 | — | — | EP | disclosed |
| US-20120015917-A1 | Use of Estrogenic Compounds in Combination with Progestogenic Compounds in Hormone-Replacement Therapy | PANTARHEI BIOSCIENCE B.V. (NL) | 2012-01-19 | — | — | US | disclosed |
| US-8071576-B2 | Fewer side effects; usable for longer period of time; lower recurrence rates after discontinuation; combination of progestogen and androgen components; kits | PANTARHEI BIOSCIENCE B.V. (NL) | 2011-12-06 | — | — | US | disclosed |
| EP-2266573-A1 | Fulvestrant formulation | AstraZeneca AB (SE) | 2010-12-29 | — | — | EP | disclosed |
| EP-1443966-A1 | METHOD OF PREVENTING OR TREATING BENIGN GYNAECOLOGICAL DISORDERS | Pantarhei Bioscience B.V. (NL) | 2004-08-11 | — | — | EP | disclosed |
| EP-1389117-A1 | MEANS AND METHOD FOR HORMONAL CONTRACEPTION | Pantarhei Bioscience B.V. (NL) | 2004-02-18 | — | — | EP | disclosed |
| EP-1293210-B1 | Means and method for hormonal contraception | PANTARHEI BIOSCIENCE BV (NL) | 2003-11-19 | — | — | EP | disclosed |
| WO-2003041741-A1 | METHOD OF PREVENTING OR TREATING BENIGN GYNAECOLOGICAL DISORDERS | PANTARHEI BIOSCIENCE B.V. (NL) | 2003-05-22 | — | — | WO | disclosed |
| WO-2003041719-A1 | METHOD OF CONTRACEPTION IN MAMMALIAN FEMALES AND PHARMACEUTICAL KIT FOR USE IN SUCH METHOD | PANTARHEI BIOSCIENCE B.V. (NL) | 2003-05-22 | — | — | WO | disclosed |
| EP-1293210-A1 | Means and method for hormonal contraception | Pantarhei Bioscience B.V. (NL) | 2003-03-19 | — | — | EP | disclosed |
| US-20020193356-A1 | Means and method for hormonal contraception | PANTARHEI BIOSCIENCE B.V. (NL) | 2002-12-19 | — | — | US | disclosed |
| WO-2002094281-A1 | MEANS AND METHOD FOR HORMONAL CONTRACEPTION | PANTARHEI BIOSCIENCE B.V. (NL) | 2002-11-28 | — | — | WO | disclosed |
| WO-2002094277-A1 | MEANS AND METHOD FOR HORMONAL CONTRACEPTION | PANTARHEI BIOSCIENCE B.V. (NL) | 2002-11-28 | — | — | WO | disclosed |